This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Egyptian Drug Authority | |
|---|---|
| Name | Egyptian Drug Authority |
| Native name | الهيئة المصرية للدواء |
| Formed | 2017 |
| Jurisdiction | Cairo, Egypt |
| Headquarters | Heliopolis |
| Chief1 name | (See Organization and Governance) |
| Website | (official website) |
Egyptian Drug Authority is the national regulatory agency responsible for oversight of pharmaceuticals, biologics, medical devices, vaccines, and controlled substances within Egypt. Founded amid reform efforts in the late 2010s, the Authority centralizes functions previously distributed across multiple ministries and agencies to streamline public health protection, market authorization, and post‑market surveillance. It operates within the framework of statutes enacted by the House of Representatives (Egypt) and interacts with regional and international partners to align national standards with World Health Organization norms.
The Authority traces origins to policy shifts following the 2011 political transition and subsequent healthcare reforms initiated by the Ministry of Health and Population (Egypt). In 2017, legislation established a standalone regulatory body replacing functions that had been housed in the Central Administration of Pharmaceutical Affairs and parts of the Egyptian Drug Authority (predecessor) structures. The creation responded to pressures from stakeholders including multinational firms represented by the American Chamber of Commerce in Egypt, domestic manufacturers such as companies in the Tenth of Ramadan City, and patient advocacy groups influenced by events similar to global safety crises like the thalidomide scandal and the hepatitis C epidemic in Egypt. Since inception, leadership has engaged with delegations from the European Medicines Agency, the United States Food and Drug Administration, and the Gulf Cooperation Council regulatory networks to modernize standards.
The Authority is structured into directorates and committees echoing models used by regulatory bodies such as the Pharmaceuticals and Medical Devices Agency and the Medicines and Healthcare products Regulatory Agency. A Board—appointed by presidential decree via the President of Egypt and advised by the Prime Minister of Egypt—oversees strategic direction and budgetary allocations subject to oversight by the Ministry of Finance (Egypt). Operational units include directorates for registration, inspection, pharmacovigilance, clinical trials, quality control, and legal affairs, each led by directors with technical backgrounds from institutions like Ain Shams University, Cairo University, and the National Research Centre (Egypt). Advisory committees draw experts from professional bodies such as the Egyptian Pharmacists Syndicate and the Egyptian Medical Syndicate.
Mandated responsibilities encompass pre‑market evaluation, market authorization, quality control, post‑market surveillance, and regulatory science initiatives paralleling mandates of the World Health Organization and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The Authority issues technical guidance on good manufacturing practices referenced to World Health Organization GMP and inspects facilities domestically and in export destinations including ports like Alexandria. It establishes therapeutic classification systems, controls schedules for narcotics coordinated with the International Narcotics Control Board, and sets biologics standards informed by collaboration with the Egyptian Organization for Standardization and Quality.
Registration pathways accommodate originator products, generics, biosimilars, and over‑the‑counter medicines with requirements patterned on dossiers recommended by the Common Technical Document format and international regulators such as the European Medicines Agency and the United States Food and Drug Administration. Applicants submit chemistry, manufacturing and controls data from certified laboratories including those accredited by the National Accreditation Council (Egypt), clinical trial data overseen under protocols aligned with the Declaration of Helsinki, and stability studies referencing climatic zones used by the World Health Organization. Expedited pathways exist for vaccines and orphan drugs, and conditional approvals may be granted in emergencies paralleling mechanisms used during the COVID‑19 pandemic.
The Authority operates a national pharmacovigilance center coordinating adverse event reporting systems linked to hospital networks such as Kasr El Aini Hospital and referral centers handling outbreaks like the 2006 H5N1 outbreak in Egypt. It maintains adverse event databases interoperable with WHO's global pharmacovigilance platforms and issues safety alerts, recalls, and risk mitigation measures. Committees evaluate periodic safety update reports, signal detection methodologies, and risk‑benefit analyses informed by epidemiological surveillance from the Ministry of Health and Population (Egypt) and laboratory confirmations from the Central Public Health Laboratory.
Inspection teams enforce compliance through Good Manufacturing Practice audits, supply‑chain inspections at ports including Port Said, and market surveillance in retail settings such as pharmacies regulated by the Egyptian Pharmacists Syndicate. Legal enforcement actions follow administrative law frameworks adjudicated in courts such as the Administrative Court (Egypt) and involve coordination with enforcement bodies including the Ministry of Interior (Egypt) for criminal investigations into counterfeit or substandard products. Sanctions range from license suspension to fines and referral for prosecution under statutes passed by the House of Representatives (Egypt).
The Authority engages in memoranda of understanding and capacity building with international counterparts including the World Health Organization, the European Medicines Agency, the United States Food and Drug Administration, and regional networks such as the African Medicines Regulatory Harmonization initiative. It participates in trade and regulatory dialogues affecting agreements negotiated by entities like the Egyptian General Authority for Investment and Free Zones and collaborates on cross‑border pharmacovigilance with neighboring states including Sudan and Libya. Membership in global fora supports harmonization efforts tied to treaties and conventions administered by the United Nations Office on Drugs and Crime and the International Council for Harmonisation.
Category:Pharmaceutical regulatory agencies